Intellia Therapeutics - NTLA Stock Forecast, Price & News

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTLA shares.
View NTLA analyst ratings or view top-rated stocks.

18 brokerages have issued 12-month price targets for Intellia Therapeutics' shares. Their NTLA share price forecasts range from $50.00 to $180.00. On average, they anticipate the company's share price to reach $110.72 in the next twelve months. This suggests a possible upside of 129.4% from the stock's current price.
View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts.

Intellia Therapeutics' stock was trading at $118.24 at the start of the year. Since then, NTLA stock has decreased by 59.2% and is now trading at $48.26.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NTLA earnings forecast.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its quarterly earnings results on Thursday, November, 3rd. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.31) by $0.18. The business earned $13.27 million during the quarter, compared to the consensus estimate of $13.60 million. Intellia Therapeutics had a negative net margin of 859.92% and a negative trailing twelve-month return on equity of 47.79%.

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.70%), Vanguard Group Inc. (8.41%), BlackRock Inc. (7.79%), Sumitomo Mitsui Trust Holdings Inc. (3.90%), State Street Corp (3.42%) and Price T Rowe Associates Inc. MD (2.21%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends.

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTLA stock can currently be purchased for approximately $48.26.

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $3.80 billion and generates $33.05 million in revenue each year. The company earns $-267,890,000.00 in net income (profit) each year or ($5.87) on an earnings per share basis.

The company employs 485 workers across the globe.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.